Technology | Antiplatelet and Anticoagulation Therapies | July 14, 2016

BBMK Technologies Launches ClotMD Mobile App for Real-time Warfarin Management

Application sends real-time alerts on INR levels, scheduled testing and medication reminders to improve patient compliance

BBMK Technologies, ClotMD mobile app, real-time warfarin management

July 14, 2016 — BBMK Technologies recently announced the launch of ClotMD, a cloud-based application and mobile solution. The software-as-a-service (SaaS)-based solution allows healthcare providers to overcome the challenges of managing patients on anticoagulant medication, specifically warfarin.

Healthcare providers can easily manage on-site testing or home INR monitoring while enhancing patient medication adherence and improving their business. With ClotMD, providers have access to a fully integrated warfarin monitoring solution, allowing patients to engage actively in their health for an improved outcome on any computer or mobile device.

Patients who are on warfarin to manage anticoagulation require consistent and ongoing testing of INR levels to maintain within therapeutic range and avoid potentially serious health implications. ClotMD is designed to help healthcare providers manage their warfarin patient population while improving day-to-day business processes. Providers can now focus on patients who require their attention when they fall outside of target therapeutic range or are non-compliant with prescribed medication and/or testing.

The app works on any computer or mobile device, providing a real-time connection between providers and patients. ClotMD allows for convenient management of INR levels, dosing calculations and testing schedules.

The ClotMD mobile app makes patient-centric care possible by delivering real-time alerts on INR levels, scheduled testing and medication reminders.  Further, patients can also receive automatic notifications from their healthcare provider alerting them to a warfarin dosage change. A built-in diet library offers another layer of support for patients who want to be proactive regarding their health. History of current and previous INR levels can be tracked and shared by the patient.

For more information: www.clotmd.com

Related Content

News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Subscribe Now